Therapy proves effective in subgroup of COPD patients
An antibody treatment has been found to reduce the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant COPD...
List view / Grid view
An antibody treatment has been found to reduce the rate of flare-ups by nearly 20 percent in patients with a subgroup of treatment-resistant COPD...
Prior to joining CRT-DL, Dr Ryder held positions in pharmaceutical and biotech companies for over 20 years ...
Lung cancer screening is likely to be cost-effective, particularly if it also identifies other tobacco-related conditions in high-risk people, suggests new research.
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. Although, still at a pre-clinical stage, these findings have important potential implications for the future treatment of patients.
Sound Pharmaceuticals has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
A collaboration to investigate the link between epigenetics and respiratory disease and to find new drug treatments involves...
15 June 2016 | By Victoria White, Digital Content Producer
MRCT and AstraZeneca are seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases...
23 September 2015 | By Victoria White
C4XD expects to progress its type 2 diabetes and inflammation programmes into in vivo proof-of-principle testing in the next few months...
22 September 2015 | By Victoria White
The companies have applied a crowdsourcing approach to establish a research team who will endeavour to identify new approaches for the treatment of patients with COPD...
15 July 2015 | By Victoria White
GSK and MRC are to collaborate on a unique open innovation research initiative aiming to improve scientists’ understanding of inflammatory diseases...
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
30 April 2015 | By Victoria White
Scientists at Helmholtz Zentrum München have succeeded in testing the effectiveness of new approaches for treating COPD on ex vivo 3D-LTCs...
2 March 2015 | By MRC Technology
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease...
11 September 2014 | By Ario Pharma
New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates...